One of the most serious and frequently neglected side-effects of parkinson’s disease (PD) is psychosis. As the condition worsens with time or due to dopaminergic treatment, hallucinations and delusions might develop. As traditional antipsychotics can aggravate motor symptoms, treating psychosis in PD is especially challenging.
Pimavanserin is a drug that provides an alternative in such situations.
What Makes Pimavanserin Unique?
In contrast to the traditional antipsychotic treatment options that inhibit dopamine D2 receptors, pimavanserin acts as a selective inverse agonist and antagonist of the serotonin 5-HT2A receptor. Essentially, the low dopaminergic activity decreases the chance that Parkinson’s sufferers’ motor function would deteriorate.
This can help the doctors to treat psychotic symptoms without severely affecting the dopamine pathways that are already weakened in PD.
Clinical Role
Parkinson’s disease psychosis (PDP) can be treated with pimavanserin. Clinical investigations showed improvements in delusions and hallucinations without a clinically significant decline in motor symptoms.
Compared to many conventional antipsychotics, which can worsen bradykinesia, tremors, and rigidity, this is a significant benefit.
Safety and Considerations
Like many psychotropic agents, pimavanserin carries important considerations:
-
QT interval prolongation risk
-
Possible increased mortality in elderly patients with dementia-related psychosis (class warning for antipsychotics)
-
High cost
-
Delayed onset of action compared to some dopamine-blocking agents
It is not approved for general dementia-related psychosis outside Parkinson’s disease.
The Bigger Picture
A more general change in psychopharmacology, from broad receptor blockage to focused receptor modulation, is exemplified by pimavanserin. It also emphasizes how crucial it is to adjust mental health care to the specifics of neurological disorders.
Drugs like pimavanserin could be the future of more targeted neuropsychiatric treatment as our knowledge of receptor-specific pharmacology develops.
Should the development of antipsychotics in the future completely abandon dopamine blocking in favour of receptor-specific modulation, such as pimavanserin?
MBH/PS